Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

145
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
145
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

131
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
131

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Threshold Effects, Cognitive Decline, and Longitudinal Changes in White Matter Hyperintensity Volume.

Stroke·2026
Same author

Vaginal Natural Orifice Transluminal Endoscopic Surgery in Minimally Invasive Gynecologic Surgery: Correction.

Obstetrics and gynecology·2026
Same author

Colocalization of eQTLs With Type 2 Diabetes and Glycemic Traits Using Whole-Genome Sequences in Diverse Populations From the NHLBI Trans-Omics in Precision Medicine (TOPMed) Program.

Diabetes·2026
Same author

A genome-wide meta-analysis identifies a sex-specific genetic effect for platelet aggregation in response to agonists.

medRxiv : the preprint server for health sciences·2026
Same author

Health disparities in perioperative complications associated with pelvic organ prolapse surgeries.

Gynecology and pelvic medicine·2026
Same author

Health Care Sustainability: Strategies for Operating Rooms and Urogynecologic Procedures.

Urogynecology (Philadelphia, Pa.)·2026

Related Experiment Video

Updated: May 31, 2025

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
08:43

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

14.7K

Treatment Crossover Following Advanced Therapy for Overactive Bladder Syndrome.

Preston Edge1, Lisa R Yanek2, Danielle Patterson1

  • 1From the Departments of Gynecology and Obstetrics.

Urogynecology (Philadelphia, Pa.)
|January 22, 2025
PubMed
Summary

Treatment crossover after advanced overactive bladder therapies is uncommon. Percutaneous tibial nerve stimulation had a higher likelihood of treatment switching compared to sacral neuromodulation or OnabotulinumtoxinA. Medication use varied across treatments.

More Related Videos

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing
05:25

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing

Published on: August 14, 2019

19.1K
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.2K

Related Experiment Videos

Last Updated: May 31, 2025

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
08:43

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

14.7K
Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing
05:25

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing

Published on: August 14, 2019

19.1K
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.2K

Area of Science:

  • Urology
  • Medical Economics

Background:

  • Overactive bladder syndrome (OAB) affects many women, with advanced therapies offering alternatives when conservative treatments fail.
  • Choosing between sacral neuromodulation (SNM), intradetrusor OnabotulinumtoxinA (BTX-A), and percutaneous tibial nerve stimulation (PTNS) involves considering treatment durability and subsequent needs.

Purpose of the Study:

  • To estimate treatment crossover rates between advanced OAB therapies.
  • To compare medication use following SNM, BTX-A, and PTNS in women with nonneurogenic OAB.

Main Methods:

  • Retrospective cohort study using MarketScan claims data (2013-2019).
  • Identified privately insured women (18-65 years) with OAB receiving an index advanced therapy.
  • Calculated proportions of patients crossing over to a different advanced therapy and those using OAB medication post-treatment.

Main Results:

  • Of 7,231 women, 4.3% crossed over to another advanced therapy.
  • Crossover was significantly more likely after PTNS (8.0%) than SNM (4.2%) or BTX-A (2.6%).
  • Medication use post-therapy was highest after PTNS (29.2%) compared to BTX-A (20.4%) and SNM (18.8%).

Conclusions:

  • Treatment crossover after advanced OAB therapy is infrequent but more common with PTNS.
  • A substantial minority of patients used OAB medication after undergoing advanced therapy, regardless of the initial treatment.